Francesco Prattichizzo

List of Publications by Year
in descending order

81	4,220	87843 38	123376 61
papers	citations	h-index	g-index

82	82	82	6364
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inflammageing and metaflammation: The yin and yang of type 2 diabetes. Ageing Research Reviews, 2018, 41, 1-17.	5.0	182
2	MitomiRs in human inflamm-aging: A hypothesis involving miR-181a, miR-34a and miR-146a. Experimental Gerontology, 2014, 56, 154-163.	1.2	179
3	The â€œMetabolic Memoryâ€•Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients, 2017, 9, 437.	1.7	169
4	Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine and Growth Factor Reviews, 2020, 53, 33-37.	3.2	146
5	T Cells: Warriors of SARS-CoV-2 Infection. Trends in Immunology, 2021, 42, 18-30.	2.9	142
6	Anti-senescence compounds: A potential nutraceutical approach to healthy aging. Ageing Research Reviews, 2018, 46, 14-31.	5.0	130
7	Cellular Senescence and Inflammaging in Age-Related Diseases. Mediators of Inflammation, 2018, 2018, 1-6.	1.4	120
8	Toll like receptor signaling in â€œinflammagingâ€• microRNA as new players. Immunity and Ageing, 2013, 10, 11.	1.8	114
9	The link between diabetes and atherosclerosis. European Journal of Preventive Cardiology, 2019, 26, 15-24.	0.8	111
10	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget, 2015, 6, 35372-35382.	0.8	107
11	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging, 2014, 6, 771-786.	1.4	105
12	Small extracellular vesicles deliver miRâ€21 and miRâ€217 as proâ€senescence effectors to endothelial cells. Journal of Extracellular Vesicles, 2020, 9, 1725285.	5.5	104
13	Where Metabolism Meets Senescence: Focus on Endothelial Cells. Frontiers in Physiology, 2019, 10, 1523.	1.3	103
14	Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. Redox Biology, 2018, 15, 170-181.	3.9	102
15	miR-21 and miR-146a: The microRNAs of inflammaging and age-related diseases. Ageing Research Reviews, 2021, 70, 101374.	5.0	100
16	â€œInflammagingâ€•as a Druggable Target: A Senescence-Associated Secretory Phenotypeâ€”Centered View of Type 2 Diabetes. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	1.9	93
17	Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is lowâ€grade inflammation the neglected component?. Diabetes, Obesity and Metabolism, 2018, 20, 2515-2522.	2.2	91
18	Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clinical Epigenetics, 2015, 7, 56.	1.8	83

#	Article	IF	Citations
19	Type 2 Diabetes: How Much of an Autoimmune Disease?. Frontiers in Endocrinology, 2019, 10, 451.	1.5	82
20	Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Research Reviews, 2018, 48, 87-98.	5.0	80
21	Why is hyperglycaemia worsening <scp>COVID</scp>â€19 and its prognosis?. Diabetes, Obesity and Metabolism, 2020, 22, 1951-1952.	2.2	78
22	Exosome-based immunomodulation during aging: A nano-perspective on inflamm-aging. Mechanisms of Ageing and Development, 2017, 168, 44-53.	2.2	76
23	Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. Cardiovascular Diabetology, 2018, 17, 105.	2.7	71
24	Anti-TNF-Î± treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. Oncotarget, 2016, 7, 11945-11958.	0.8	69
25	Anti-inflammatory effect of ubiquinol-10 on young and senescent endothelial cells via miR-146a modulation. Free Radical Biology and Medicine, 2013, 63, 410-420.	1.3	65
26	Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naÃ¯ve T2D. Cardiovascular Diabetology, 2019, 18, 18.	2.7	63
27	Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. Diabetes, Obesity and Metabolism, 2016, 18, 855-867.	2.2	57
28	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. European Journal of Preventive Cardiology, 2019, 26, 73-80.	0.8	56
29	The pleiotropic roles of leptin in metabolism, immunity, and cancer. Journal of Experimental Medicine, 2021, 218, .	4.2	54
30	Variability of risk factors and diabetes complications. Cardiovascular Diabetology, 2021, 20, 101.	2.7	54
31	NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2019, 8, 720.	1.0	52
32	Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. Theranostics, 2021, 11, 1031-1045.	4.6	52
33	Senescence associated macrophages and â€œmacroph-agingâ€: are they pieces of the same puzzle?. Aging, 2016, 8, 3159-3160.	1.4	51
34	Glycaemic management in diabetes: old and new approaches. Lancet Diabetes and Endocrinology,the, 2022, 10, 75-84.	5.5	50
35	Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	48
36	The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine, 2017, 56, 509-520.	1.1	47

#	Article	IF	Citations
37	Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy â€“ A study with monozygotic twin pairs. Mechanisms of Ageing and Development, 2014, 143-144, 1-8.	2.2	45
38	Leukocyte telomere length and mortality risk in patients with type 2 diabetes. Oncotarget, 2016, 7, 50835-50844.	0.8	44
39	Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity, 2021, 54, 1543-1560.e6.	6.6	42
40	Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. Metabolism: Clinical and Experimental, 2020, 110, 154308.	1.5	41
41	Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1696-1700.	2.2	40
42	Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cellular and Molecular Life Sciences, 2022, 79, 273.	2.4	40
43	CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. Diabetes, 2021, 70, 240-254.	0.3	38
44	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	2.7	38
45	Extracellular vesicles circulating in young organisms promote healthy longevity. Journal of Extracellular Vesicles, 2019, 8, 1656044.	5.5	36
46	The mitomiR/Bcl-2 axis affects mitochondrial function and autophagic vacuole formation in senescent endothelial cells. Aging, 2018, 10, 2855-2873.	1.4	34
47	Elevated HbA1c levels in preâ€Covidâ€19 infection increases the risk of mortality: A systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2022, 38, e3476.	1.7	34
48	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nature Communications, 2022, 13, 2318.	5.8	33
49	Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism: Clinical and Experimental, 2021, 120, 154799.	1.5	32
50	Pleiotropic effects of polyphenols on glucose and lipid metabolism: Focus on clinical trials. Ageing Research Reviews, 2020, 61, 101074.	5.0	30
51	HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target. Cardiovascular Diabetology, 2022, 21, 13.	2.7	28
52	Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes. Diabetologia, 2020, 63, 2699-2712.	2.9	25
53	Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity. International Journal of Molecular Sciences, 2020, 21, 477.	1.8	25
54	Senescent macrophages in the human adipose tissue as a source of inflammaging. GeroScience, 2022, 44, 1941-1960.	2.1	25

#	Article	IF	Citations
55	Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. Cell Death and Disease, 2013, 4, e594-e594.	2.7	23
56	Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools. Current Drug Targets, 2016, 17, 388-397.	1.0	23
57	Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM. Oncotarget, 2017, 8, 93338-93348.	0.8	21
58	MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab. British Journal of Dermatology, 2018, 179, 787-789.	1.4	19
59	Inflamm-aging microRNAs may integrate signals from food and gut microbiota by modulating common signalling pathways. Mechanisms of Ageing and Development, 2019, 182, 111127.	2.2	19
60	Novel insights into the regulation of miRNA transcriptional control: implications for T2D and related complications. Acta Diabetologica, 2018, 55, 989-998.	1.2	16
61	Two drugs are better than one to start T2DM therapy. Nature Reviews Endocrinology, 2020, 16, 15-16.	4.3	16
62	Effect of time and titer in convalescent plasma therapy for COVID-19. IScience, 2021, 24, 102898.	1.9	16
63	Chemical composition and â€œ in vitro â€•anti-inflammatory activity of Vitis vinifera L. (var. Sangiovese) tendrils extract. Journal of Functional Foods, 2016, 20, 291-302.	1.6	15
64	Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs. Scientific Reports, 2020, 10, 21782.	1.6	14
65	Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. Frontiers in Endocrinology, 2020, 11, 254.	1.5	14
66	Pharmacological management of COVID-19 in type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107927.	1.2	14
67	Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register. Cardiovascular Diabetology, 2021, 20, 173.	2.7	14
68	Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms. Journal of Clinical Medicine, 2022, 11, 1564.	1.0	13
69	Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. Oncotarget, 2018, 9, 8898-8910.	0.8	11
70	The In Vitro Activity of Angelica archangelica L. Essential Oil on Inflammation. Journal of Medicinal Food, 2018, 21, 1238-1243.	0.8	10
71	Response to: Letter to the Editor on â€œBonafÃ¨ M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Revâ€•by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella. Cytokine and Growth Factor Reviews, 2021, 58, 141-143.	3.2	9
72	DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 1519-1531.	1.1	9

#	Article	IF	Citations
73	One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study. BMJ Open Diabetes Research and Care, 2020, 8, e001331.	1.2	6
74	Is time ready for combination therapy at diagnosis of type 2Âdiabetes?. Diabetes/Metabolism Research and Reviews, 2021, 37, e3460.	1.7	5
75	Ageing as a druggable process: Moving forward. EBioMedicine, 2019, 40, 15-16.	2.7	4
76	Positioning newer drugs in the management of type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 138-139.	5.5	4
77	Tackling the pillars of ageing to fight COVID-19. The Lancet Healthy Longevity, 2021, 2, e191.	2.0	4
78	CD4+ T-Cell Activation Prompts Suppressive Function by Extracellular Vesicle-Associated MicroRNAs. Frontiers in Cell and Developmental Biology, 2021, 9, 753884.	1.8	3
79	Role of inflamma-mitomiRs miR-146a, miR-181a and miR-34a in regulating mitochondrial dysfunction during replicative senescence of human endothelial cells. Free Radical Biology and Medicine, 2017, 108, S98.	1.3	0
80	The beneficial effects (on cardio-renal system) of glucose-lowering agents with caloric-restriction mimetic properties are subtractive rather than additive. Diabetes Research and Clinical Practice, 2020, 163, 108030.	1.1	0
81	Type 1 Diabetes and Associated Cardiovascular Damage: Contribution of Extracellular Vesicles in Tissue Crosstalk. Antioxidants and Redox Signaling, 2021, , .	2.5	0